Erratum to: Detection of ATM germline variants by the p53 mitotic centrosomal localization test in BRCA1/2-negative patients with early-onset breast cancer
Andrea Prodosmo(Cellular Therapeutics (United Kingdom)), Silvia Soddu(Cellular Therapeutics (United Kingdom)), Paola Pinnarò, Marialuisa Appetecchia(Istituti di Ricovero e Cura a Carattere Scientifico), Giuseppe Giannini(Istituto Pasteur), Maurizio Cosimelli(National Cancer Institute), Aurora De Leo(National Cancer Institute), Enrico Vizza(Human Technopole), Anna Coppa(Sapienza University of Rome), Agnese Barnabei(National Cancer Institute), Manlio Mattioni(Cellular Therapeutics (United Kingdom)), Salvatore Sciacchitano(Hospital Universitario de La Princesa), Francesco Facciolo(National Cancer Institute), Giacomo Corrado(Agostino Gemelli University Polyclinic), Gabriele Alessandrini(National Cancer Institute), Arianna Nicolussi(Sapienza University of Rome), Lidia Strigari(Azienda USL di Bologna), Agnese Persichetti(National Cancer Institute), C. Giordano(Istituti di Ricovero e Cura a Carattere Scientifico), Gian Luca Grazi(Azienda Ospedaliero-Universitaria Careggi), Amelia Buffone(Sapienza University of Rome), Giuseppe Sanguineti(National Cancer Institute)
Cited by 1
Related Papers
Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis
|The Lancet Oncology|2008|2k
Head and Neck Cancers
|Journal of the National Comprehensive Cancer Network|2011|415
Cross-reactivity between tumor MHC class I–restricted antigens and an enterococcal bacteriophage
|Science|2020|382
Galectin-3: One Molecule for an Alphabet of Diseases, from A to Z
|International Journal of Molecular Sciences|2018|370
Carcinoma of the nasopharynx treated by radiotherapy alone: Determinants of local and regional control
|International Journal of Radiation Oncology*Biology*Physics|1997|279